Patents by Inventor Thierry Sifferlen

Thierry Sifferlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20170305897
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. Williams
  • Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
    Patent number: 9790208
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 17, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Benzimidazole-proline derivatives
    Patent number: 9732075
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: August 15, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20170001985
    Abstract: The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 3, 2014
    Publication date: January 5, 2017
    Inventors: Christoph BOSS, Catherine ROCH, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Francois JENCK, Thierry SIFFERLEN, Michel STEINER, Jodi T. WILLIAMS
  • CRYSTALLINE FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1 -YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AND ITS USE AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160368901
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Application
    Filed: December 2, 2014
    Publication date: December 22, 2016
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS
  • CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST
    Publication number: 20160355506
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Application
    Filed: December 2, 2014
    Publication date: December 8, 2016
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS
  • Orexin receptor antagonists which are [bi-(hetero-)aryl]-[2-(bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
    Patent number: 9493446
    Abstract: The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 15, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Azetidine amide derivatives as orexin receptor antagonists
    Patent number: 9403813
    Abstract: The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 2, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Pyrazole and imidazole derivatives useful as orexin antagonists
    Patent number: 9303023
    Abstract: The present invention relates to pyrazole and imidazole derivatives of formula (I) wherein U, V, L, X, Y, R1, (R2)n and (R3)m and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: April 5, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160024064
    Abstract: The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 28, 2016
    Inventors: Martin BOLLI, Christoph BOSS, Christine BROTSCHI, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. WILLIAMS
  • Lactam derivatives useful as orexin receptor antagonists
    Patent number: 9242970
    Abstract: The present invention relates to lactam derivatives of formula (I) wherein Y, R1, R2 and R3 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: January 26, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Christine Brotschi, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Proline sulfonamide derivatives as orexin receptor antagonists
    Patent number: 9211279
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: December 15, 2015
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Christoph Boss, Christine Brotschi, John Gatfield, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
    Patent number: 9150566
    Abstract: The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: October 6, 2015
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
    Publication number: 20150252032
    Abstract: The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: October 9, 2013
    Publication date: September 10, 2015
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20150246021
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I), wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Application
    Filed: March 5, 2015
    Publication date: September 3, 2015
    Inventors: Christoph BOSS, Christine BROTSCHI, John GATFIELD, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. WILLIAMS
  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20150166527
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: June 3, 2013
    Publication date: June 18, 2015
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20150158855
    Abstract: The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: November 7, 2012
    Publication date: June 11, 2015
    Applicant: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Proline sulfonamide derivatives as orexin receptor antagonists
    Patent number: 9000029
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Christoph Boss, Christine Brotschi, John Gatfield, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20150057328
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 26, 2015
    Inventors: Christoph BOSS, Christine BROTSCHI, John GATFIELD, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. WILLIAMS
  • Proline sulfonamide derivatives as orexin receptor antagonists
    Patent number: 8895606
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: November 25, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Christoph Boss, Christine Brotschi, John Gatfield, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams